MLN3126
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 09, 2018
MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model.
(PubMed, Int Immunopharmacol)
- "Anti-TNF-α antibody, a surrogate for a standard of care for IBD treatment, was also efficacious in the colitis model. These results suggest that MLN3126 would be a promising orally available CCR9 antagonist to treat colonic IBD."
Journal • Preclinical • Biosimilar • Immunology • Inflammation • Inflammatory Bowel Disease
April 15, 2015
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
(clinicaltrials.gov)
- P1; N=23; Terminated; Sponsor: Takeda; N=64 -> 23 ; Suspended -> Terminated ; Trial primary completion date: Mar 2015 ->Oct 2014
Enrollment change • Trial primary completion date • Trial termination • Biosimilar
1 to 2
Of
2
Go to page
1